Sold as Pentetate Calcium Trisodium. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Pentetate Calcium Trisodium (sold as Pentetate Calcium Trisodium), first approved Aug 11, 2004, with 0 new uses approved and 0 published complete response letters.
| Development of a Noninvasive Metric to Measure Small Bowel Sensation - The Small Intestine Stress TestDisorders of Gut Brain Interaction · Mayo Clinic | Not applicable | Recruiting | Sep 14, 2026 |
| A Comparative Study of Normalized Residual Activity and Standard Parameters in 99mTc-DTPA Diuretic Renography:Urinary Tract Obstruction · Assiut University | — | Not yet recruiting | Sep 10, 2026 |
| Advanced Diffusion Imaging in Renal Cancer PatientsRenal Cancer · NYU Langone Health | Not applicable | Active, not recruiting | Nov 3, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 11, 2004 | Pentetate Calcium TrisodiumNDA 21749 · New molecular entity | Hameln | 4 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
